NEJM August 2026 Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica

This study investigates the efficacy of secukinumab, a monoclonal antibody, as a novel treatment for patients suffering from relapsed polymyalgia rheumatica. Because traditional steroid therapies often lead to dangerous side effects and frequent relapses, researchers tested whether blocking the interleukin-17A protein could provide a safer, more stable alternative. The results demonstrated that patients receiving the drug were significantly more likely to achieve sustained remission while requiring a lower cumulative dose of glucocorticoidscompared to those on a placebo. Ultimately, the trial suggests that secukinumab serves as a promising steroid-sparing agent that effectively manages inflammation and reduces the long-term burden of hormonal medication.